Opinion|Videos|June 19, 2023
Assessing and Treating Patients with High-Risk NDMM
Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.
Advertisement
Episodes in this series
Advertisement
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
In the phase 1/2 Bela-DRd study, over 90% of patients responded to belantamab mafodotin plus daratumumab, lenalidomide, and dexamethasone.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
4
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
5